C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 401/10 (2006.01) A61K 31/496 (2006.01) A61K 31/5377 (2006.01) A61P 25/00 (2006.01) C07D 401/14 (2006.01) C07D 413/14 (2006.01)
Patent
CA 2528756
The present invention relates to compounds of formula (I) wherein X and Y are as defined in the specification, and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.
L'invention concerne des composés de formule I, dans laquelle X et Y ont la définition donnée dans la description, et des compositions pharmaceutiques qui contiennent un composé de formule I et un excipient pharmaceutiquement efficace, ainsi qu'un procédé utile pour traiter ou pour prévenir chez des mammifères, y compris des êtres humains, des troubles ou des états pathologiques sélectionnés dans un groupe constitué par l'angoisse, la dépression, la dhysthymie, les troubles dépressifs importants, la migraine, le syndrome de stress post-traumatique, la personnalité évitante, le trouble de la personnalité limite et les phobies.
Pfizer Products Inc.
Smart & Biggar
LandOfFree
Tetrahydroisoquinolines as antagonists of the 5ht1b receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydroisoquinolines as antagonists of the 5ht1b receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydroisoquinolines as antagonists of the 5ht1b receptor will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1878608